Table 3 Responses by subgroups
From: Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
Age | mSMART risk | Prior bortezomib | Prior lenalidomide | |||||
|---|---|---|---|---|---|---|---|---|
<65 (n=13) | ⩾65 (n=19) | High (n=4) | Standard (n=28) | Yes (n=9) | No (n=23) | Yes (n=25) | No (n=7) | |
Response to single agent ixazomib | ||||||||
sCR | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 |
CR | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 |
VGPR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PR | 1 | 2 | 1 | 2 | 1 | 2 | 1 | 2 |
MR | 3 | 1 | 0 | 3 | 0 | 3 | 3 | 0 |
Overall response | ||||||||
sCR | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 |
CR | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 |
VGPR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PR | 4 | 5 | 2 | 7 | 3 | 6 | 6 | 3 |
MR | 1 | 3 | 0 | 3 | 2 | 2 | 4 | 0 |
